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Aims Atrial fibrillation (AF) is a progressive cardiac arrhythmia that increases the risk of hospitalization and adverse car-
diovascular events. There is a clear demand for more inclusive and large-scale approaches to understand the molec-
ular drivers responsible for AF, as well as the fundamental mechanisms governing the transition from paroxysmal to
persistent and permanent forms. In this study, we aimed to create a molecular map of AF and find the distinct mo-




We used a sheep model of long-standing, tachypacing-induced AF, sampled right and left atrial tissue, and isolated
cardiomyocytes (CMs) from control, intermediate (transition), and late time points during AF progression, and per-
formed transcriptomic and proteome profiling. We have merged all these layers of information into a meaningful
three-component space in which we explored the genes and proteins detected and their common patterns of ex-
pression. Our data-driven analysis points at extracellular matrix remodelling, inflammation, ion channel, myofibril
structure, mitochondrial complexes, chromatin remodelling, and genes related to neural function, as well as critical
regulators of cell proliferation as hallmarks of AF progression. Most important, we prove that these changes occur
at early transitional stages of the disease, but not at later stages, and that the left atrium undergoes significantly
more profound changes than the right atrium in its expression programme. The pattern of dynamic changes in gene
and protein expression replicate the electrical and structural remodelling demonstrated previously in the sheep and
in humans, and uncover novel mechanisms potentially relevant for disease treatment.
....................................................................................................................................................................................................
Conclusions Transcriptomic and proteomic analysis of AF progression in a large animal model shows that significant changes oc-
cur at early stages, and that among others involve previously undescribed increase in mitochondria, changes to the
chromatin of atrial CMs, and genes related to neural function and cell proliferation.
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Atrial fibrillation (AF) is the most common arrhythmia. Estimates indicate
that it affects over 33 million people worldwide,1 and US Census projec-
tions estimate that by 2050 incidence of AF will more than double.2 AF
typically starts with brief paroxysmal episodes that in many patients
evolve, lasting progressively longer until AF becomes persistent and then
permanent. Progression from paroxysmal to persistent AF is accompa-
nied by incremental functional and structural modification of the atria
that permits its long-term perpetuation.3 Such changes also increase the
risk of hospitalization and subsequent cardiovascular events.4 However,
the fundamental mechanisms governing the conversion from paroxysmal
to persistent and permanent forms are not well understood, leading to
poor prevention and suboptimal treatment. Thus, there is a clear need
for more inclusive and large-scale approaches to understand the molecu-
lar mechanisms responsible of the disease.
Obtaining reliable samples from patients is difficult. Therefore, differ-
ent animal models have been fundamental to understand the mechanism
underlying AF onset and progression.5–7 We have previously shown that
in a clinically relevant sheep model of tachypacing induced, long-standing
persistent AF, the duration of the AF episodes increase progressively at a
rate that predicts the time at which AF stabilizes and becomes persis-
tent.3,8 In a recent clinical study, remote transmissions of atrial activation
frequency in patients with implantable cardioverter-defibrillator ±
resynchronization therapy or pacemaker devices enabled the demon-
stration that the evolution of the AF-induced atrial electrical remodelling
follows a remarkably similar general pattern as the sheep model.9 In the
sheep, the changes in AF frequency and duration reflected changes in ac-
tion potential duration and densities of ion currents.3 There were also
gradual changes in atrial structure including atrial dilatation, hypertrophy,
and fibrosis, all of which were mitigated, but not prevented by upstream
therapy with antifibrotic agents like eplerenone and a galectin-3 inhibi-
tor.10,11 The above results in animals and patients highlighted the impor-
tance of investigating the mechanisms of AF progression. They also
provided strong evidence that monitoring the progression of atrial elec-
trical remodelling can help physicians in the stratification and personal-
ized care of AF patients.9
In this work, we have characterized the transcriptomic and proteomic
dynamics that result in progressive remodelling of both atria, making the
arrhythmia more stable and long-lasting. We used a well-established ex-
perimental model of intermittent atrial tachypacing3,11 and created a
user-friendly and interactive web application to enhance and facilitate
data sharing in our search for gene and protein expression changes that
underlie AF-induced atrial remodelling.
2. Methods
2.1 Experimental animals
We induced AF using atrial tachypacing as described previously.3,8 Three
groups of male sheep were used: transition (13.75± 4.50 days of self-
sustained AF without reversal to sinus rhythm), chronic or long-standing
persistent AF (289.25 ± 50.29 days of self-sustained AF without reversal
to sinus rhythm), and control group (sinus rhythm). Induction of anaes-
thesia was done with intravenous propofol (4–6 mg/kg), and maintained
with isoflurane gas (5–10 mL/kg). Euthanasia was attained by removal of
the heart under anaesthesia. Animal procedures were approved by the
University of Michigan Committee on Use and Care of Animals and con-
formed to National Institutes of Health guidelines.
2.2 Transcriptomics and proteomics
Hearts were removed by thoracotomy and placed in cold cardioplegic
solution. Samples from left atrial appendage (LAA) and right atrial ap-
pendage (RAA), or from the posterior left atria (PLA) were dissected and
snap-frozen. CM isolation from LAA and RAA was performed as previ-
ously described.3 RNA-seq (LAA and RAA tissue and CMs, n = 3 for con-
trol, transition and chronic groups; PLA tissue, n = 6 for control and
transition groups) was performed by CNIC Genomic Unit using an
Illumina Hiseq 2500 sequencer, and liquid chromatography tandem–mass
spectrometry (LC-MS/MS) by the CNIC Proteomics Unit (LAA and RAA
tissue and CMs, n = 3 for control, transition and chronic groups).
2.3 Data analysis and integration
Only those genes or proteins (which we collectively term as ‘features’)
from sheep with clear human homologues were used, keeping 11 962
unique gene symbols from the human genome. We applied Multiple Co-
Inertia Analysis12 as a method for unsupervised dimensionality reduction,
necessary for the analysis of such large databases. Principal components
analysis showed that components 1–3 explain42% of the total variabil-
ity in the data, so these were retained for further analysis. Gaussian mix-
ture model (GMM) was used as an unsupervised clustering method to
identify in an unbiased way grouping of the selected features.
We performed functional enrichment analysis of the features of these
groups using Gene Ontology,13 in order to identify biological functions
or processes statistically over represented among the genes and proteins
of each group. Epigenetic modifiers were obtained from the curated
database dbEM.14 Transposable elements (TEs) were annotated and
manually curated with the repeat masker track from the UCSC Genome
Browser (Oar3.1). Gene set enrichment analysis of genome-wide associ-
ation studies (GWAS) was performed using gene lists from the public
GWAS Catalogue and from meta-analysis of AF-associated genes.15,16
RNA-seq data have been deposited at the Gene Expression Omnibus
(GEO Database GSE138255) and proteomic data at the Proteome
Xchange Consortium (PXD015637). An interactive Shiny app to browse
and analyse the full data is available at https://bioinfo.cnic.es/AFibOmics.
2.4 Protein analysis
For western blots, cells were harvested in RIPA buffer containing prote-
ase inhibitors, resolved in 15% SDS-polyacrilamide gels, and transferred
to polyvinylidene difluoride membranes. Bands were quantified using
ImageJ and normalized to Troponin T2 (TNNT2). Blue native gel elec-
trophoresis (BNGE) were performed from mitochondria extracts from
LAA and RAA isolated CMs (between 2–5 106) as described.17
3. Results
3.1 Distinct molecular changes occur
rapidly at the transition to early
persistent AF
To understand the dynamics of expression that take place during the
progression of AF, we took advantage of a well-established model of
tachypacing-induced long-standing AF in the sheep.3,8 We sampled tissue
from both the LAA and RAA from three male sheep each as follows:
control, transition (1–2 weeks of persistent self-sustained AF in the ab-
sence of tachypacing), and chronic (more than 10 months of self-
sustained persistent AF) groups (Figure 1A and Supplementary material
online, Table S1). We used LAA and RAA whole-tissue samples for




















..transcriptomic profiling by RNA-seq. We also isolated CMs from LAA
and RAA samples and performed both RNA-seq and LC-MS/MS proteo-
mic profiling (Figure 1A).
To perform this study, we have used three replicates, in line with the
normal practice in the field, where statistical methods have been devel-
oped specifically to tackle small sample sizes.18,19 However, we also ana-
lysed the intergroup variability by performing unsupervised clustering of
the results. This showed how variability among groups (control,
transition, or chronic) is lower than between groups and they cluster to-
gether (Supplementary material online, Figure S1A). Overall, we detected
13 187 and 13 262 transcripts from whole tissue and CMs samples, re-
spectively, of which a total of 1367 and 2479 genes were differentially
expressed (5% false discovery rate, FDR) in at least one of the compari-
sons carried out (Supplementary material online, Table S2). On the other
hand, we identified 7283 proteins in CMs, from which 581 had significant
differential abundances (5% FDR).
Figure 1 Transcriptomic profiling of a sheep model of AF progression. (A) Schematic diagram of the experimental strategy, the collected samples from
the left (LA) and right (RA) atrial appendages and the analyses that were carried out. Three samples were collected in each case and for each analysis. (B and
C) Correlation of mean expression values as log of counts per million (CPM) in atrial tissue RNA-seq between transition and control (left panel), chronic
and control (middle panel), and chronic and transition (right panel) from left (B, LAA) and right (C, RAA) atrial appendages. Orange and blue indicate, respec-
tively, up- and down-regulated genes for each comparison. The Pearson coefficient of correlation is indicated on the lower right corner of each plot. (D)
Progression of changes in gene expression in atrial tissue along persistent AF. The linear regression adjustment of control-to-transition logFC (fold-change)
to those of control-to-chronic (left panels) and transition-to-chronic (right panels), in left (upper panels) and right (lower panels) atrial tissue is shown.
Orange and blue indicate up- and down-regulated genes. The R2 value is indicated on the lower right corner of each plot.



































































































To assess how well changes in mRNA and protein expression corre-
lated in our system, we compared log fold-changes between control and
transition, as well as control and chronic stages of disease progression
from transcriptomic and proteomic data we generated from LAA and
RAA CMs. Correlation was relatively low but evident (Supplementary
material online, Figure S1B), and in line to what has been previously
reported.20,21
We initially performed comparisons of both transcriptomic and pro-
teomic profiles between control, transition and chronic groups from
LAA and RAA. Pairwise correlations of LAA tissue RNA-seq showed
that changes to the control condition increase with disease progression
(from the transition to the chronic group); however, when we compared
transition and chronic groups, we recovered no differentially expressed
genes (Figure 1B). We observed the same trend for the comparisons of
both RNA-seq and LC-MS/MS of LAA CMs (Supplementary material on-
line, Figure S2A and B). As for the RAA, changes for both tissue and CMs
were much lower but followed the same trend and again we detected
no changes between transition and chronic states (Figure 1C and
Supplementary material online, Figure S2A and B). Therefore, this initial
analysis suggests that the LAA undergoes more profound changes during
its progression to persistent AF than the RAA. It is also noteworthy that
no transcriptomic or proteomic changes are observed from early persis-
tent AF (transition) to long-standing persistent AF (chronic) in LAA or
RAA for any of the comparisons.
To explore further the above observation, we compared the degree
of change for all expressed genes and proteins (measured as log-fold
changes) between control and transition groups to that of control versus
chronic or transition versus chronic. In whole atrial appendage tissue
RNA-seq, there is a positive linear relationship between the changes oc-
curring from control to transition and control to chronic, indicating that
the same trend in expression variation occurs along disease progression
(Figure 1D, left panels). However, these changes level out and lead to a
flat or even slightly descending relation when we compare transition to
chronic states (Figure 1D, right panels). We observe the same behaviour
for both RNA-seq (Supplementary material online, Figure S2C) and pro-
teomic data (Supplementary material online, Figure S2D) from purified
CMs. This analysis thus confirms that the mayor events related to AF
progression occur during early phases of the disease and later stabilize as
the animal moves from the transition towards the chronic state. We be-
lieve this pattern could not be secondary to mayor morphological
changes taking place during AF progression, such as the increase in atrial
dimensions that occur by dilation of the myocardium.3 Measurement of
the differences in atrial area shows that it increases steadily from control
to chronic sheep, and does not level out from transition to chronic as
does occur with transcriptional and proteomic changes (Supplementary
material online, Figure S3A).
Remarkably, the temporal dynamics of the above changes in gene and
protein expression corresponded closely with the electrical and struc-
tural remodelling we demonstrated previously in the sheep,3 where
dominant frequency measurements in chronic (long-standing persistent
AF) sheep did not significantly change compared with the values
recorded at transition (early persistent) stage (Supplementary material
online, Figure S3B).
3.2 A three-component model explains
molecular variation during AF progression
To understand these early changes in the expression dynamics, we ana-
lysed the variability of our multiple datasets and established an integrative
data analysis model. Given the complexity of the data and the multiple
layers of information (control, transition, and chronic disease states;
LAA and RAA samples; whole atrial appendage tissue and isolated CMs;
transcriptomics and proteomics; Figure 1A), we applied dimensionality
reduction methods for data integration.22 We first analysed each techni-
cal dataset (atrial appendage tissue RNA-seq, CM RNA-seq, and CM LC-
MS/MS) separately by non-symmetric correspondence analysis, which
transforms each dataset into a series of unsupervised lower dimensional
units. In this way, we identified 18 principal components that behaved in
a similar fashion in the three datasets (Supplementary material online,
Figure S4A). To integrate the three experiments, we performed co-
inertia analysis23 among datasets obtaining a ranked order of pseudo-
eigenvalues that explained the variability of the data (Supplementary ma-
terial online, Figure S4B).
We next explored the biological sources of variation that could under-
lie each of these components, and found that the progression of the dis-
ease from control to chronic explains the first principal component
(PC1), accounting for 17.6% of the total variation in the data (disease pro-
gression; Figure 2A, B and Supplementary material online, Figure S4C). The
second component (PC2, 15.4% of variation) represents the regional dif-
ferences between LAA and RAA (left/right identity; Figure 2A and
Supplementary material online, Figure S4C). Interestingly, we observed
that the third component (PC3, 8.4% of variation) groups together sam-
ples from control and chronic individuals, separating them from transition
individuals (transition state; Figure 2B and Supplementary material online,
Figure S4C). This was an unexpected finding, but it reinforced our previous
observations (see above) that the mayor changes occurring during disease
progression occur during the transition from paroxysmal to persistent AF.
We could not identify other possible effects that would account for fur-
ther components of the variation (Supplementary material online, Figure
S4C), so we decided to use the first three components, which together ex-
plain more than 40% of the total variability, to model and analyse the mo-
lecular mechanisms underlying AF progression.
3.3 Defining the molecular features
responsible for atrial divergence and
disease progression
We subsequently characterized the molecular changes occurring during
AF progression using two different criteria to select features (genes and/
or proteins) from our RNA-seq and proteomic analysis. On one hand, we
selected features showing differential expression in any of the pairwise
comparisons (Supplementary material online, Table S2 and Figure S5A, B)
significantly detected at 5% FDR (Benjamini–Hochberg correction). This
resulted in a list of 3278 differentially expressed genes and proteins (DEG/
P; Supplementary material online, Table S2 and Figure S5D). On the other
hand, we selected features showing extreme values (outer 10%) in our
three-component space (Supplementary material online, Figure S5C),
which totalled 1790 extreme-value genes and proteins (exG/P;
Supplementary material online, Table S2 and Figure S5D). Both groups
overlapped in 658 features (Supplementary material online, Figure S5D), in-
cluding key factors with atrial-restricted expression (such as PITX2 or
BMP10) or related to atrial physiology (IL6R, KCNN2, NPPA, or RCAN1). In
total, we retained 4410 features for further analysis.
To better understand the biological relevance of these features and
their behaviour, selected features were analysed by unsupervised cluster-
ing using GMM and separated into 31 independent clusters (g_0-g_30;
Supplementary material online, Table S2) distributed along the three-
component space as defined above (Figure 2C and D). The majority of




























.clusters showed contribution to more than one component, but those
contributing significantly to the third component (PC3, transition state)
axis were less abundant (Figure 2D). Examination of mean expression of
genes or proteins from selected clusters showed direct relationship to the
location of the cluster in the three-component space (Figure 3A–D). For
example, cluster 0 (g_0) that includes among others the genes coding
for the calcineurin regulator RCAN1 or Galectin-3 binding protein
(LGALS3BP), contributes to disease progression and to a lesser extent to
left/right identity and to transition state. Expression levels increase in all
conditions from control to transition, and remain mainly stable from
transition to chronic (Figure 3A). Cluster g_6 is interesting in that it
shows an extreme position along all three components (Figure 3B) and
includes PITX2, a left atrial marker and the gene most strongly associated
to AF by GWAS,24 or PCP4, a calmodulin regulator with specific expres-
sion in cardiac Purkinje cells.25 Cluster g_20 is mostly related to disease
progression, showing a trend for down-regulation of expression
(Figure 3C). This cluster includes receptors for glucagon-like peptide 1
(GLP1R) or relaxin (RXFP1), both related to the control of insulin secre-
tion. Cluster g_24, where we find key features related with atrial physiol-
ogy such as the potassium channel gene KCNH2, or the nuclear receptor
gene NR4A3, is strongly associated with the transition state. As such, in
CM RNA-seq, we observe diminished expression in transition samples
as compared to controls, which does not occur in chronic sheep
(Figure 3D). Thus, this three-component model, allows us to explore the
contribution of significative features to better understand the progres-
sion of AF.
Figure 2 Co-inertia analysis of multidimensional data identifies the main components that drive variability in the sheep AF model. (A) Distribution of tran-
scriptomic and proteomic samples (n = 3) in relation to principal components PC1 (disease progression) and PC2 (left/right identity). Lines connect paired
samples, obtained from the same individual. Control, green; transition, purple; chronic, orange. LAA samples, dark colours; RAA samples, light colours.
Atrial tissue RNA-seq, circles; cardiomyocyte RNA-seq, diamonds; cardiomyocyte LC-MS/MS, squares. (B) Distribution of transcriptomic and proteomic
samples in relation to components PC1 (disease progression) and PC3 (transition state). Legend as in A. (C and D) Position of each of the thirty-one clusters
identified by GMM unsupervised clustering along the axis that define disease progression and left/right identity (A) or transition state (B). The size of each
cluster represented on the plot correlates with the number of features (genes and proteins) that it includes. Colour legend is shown below. Arrows indicate
the position of representative clusters (see Figure 3).
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Figure 3 Distribution and expression of representative GMM clusters in the three-component space of AF progression. The position of all individual fea-
tures of the specified GMM clusters (A, g_0; B, g_6; C, g_20; D, g_24) along the disease progression axis and left/right identity (top) or transition state (mid-
dle). Below, violin plots depicting the expression of the features from the specified cluster in each individual experiment (atria RNA-seq, cardiomyocyte
RNA-seq, and cardiomyocyte LC-MS/MS), condition (control, transition, and chronic) for both LAA and RAA; mean expression is indicated by a horizontal
black line. No proteomic data was available for cluster g_6. Colour legend of the GMM clusters is as in Figure 2.



































































































3.4 Distinct genetic programmes underlie
cell type-specific variation in AF
To gain further insight into the molecular changes occurring during AF
progression, we carried out functional enrichment analysis of each of the
GMM clusters described above. We searched for statistically enriched
Gene Ontology (GO13) terms among the features of each cluster, and
discerned which of the three different experiments was contributing to
this enriched annotation (Supplementary material online, Figure S6 and
Table S3). We were able to identify changes in gene or protein expres-
sion coming mainly from what we reckon are non-CM cells (those terms
enriched in atria RNA-seq data but not in CM data), or post-
transcriptional regulatory events (enriched in LC-MS/MS but not RNA-
seq data).
As such, terms related to extracellular matrix were enriched in several
clusters, showing a trend of increased gene expression during AF pro-
gression but mainly in whole-atrial appendage tissue and not in CMs
(Supplementary material online, Figure S6A). This suggests that these
changes occur in non-CM cells, most surely atrial fibroblasts, and relate
to the increased fibrosis that has been described during AF progres-
sion.3,26 Genes belonging to other broad categories, such as inflamma-
tion or ion channels, change in both atrial tissue and CMs
(Supplementary material online, Figure S6B and C), suggesting a complex
interplay between different cell types during disease progression. Ion
channels genes show an interesting pattern of expression changes.
While various potassium (KCNJ3, KCNJ5), calcium (CACNA1C) or sodium
(SCN5A) channel genes show a decrease in expression in CMs in AF,
most prominent when comparing control and transition samples
(Supplementary material online, Figure S6C), other components such as
HCN2 or KCNH7 are increased. These data are compatible with previous
results in sheep atrial tissue showing increased or decreased protein lev-
els of ion channels upon transition to persistent AF.3
We also found a large group of annotations related to heart muscle
and myofibril structure (Supplementary material online, Figure S6D). As
expected, changes in these genes were detected almost exclusively in
CM samples. Again, here we find genes with different behaviours. Those
genes belonging to cluster g_29 and annotated as contractile fibre con-
tain genes such as cardiac muscle alpha actin (ACTC1) or myosin heavy
chain 2 (MYH2), and show a general trend of down-regulation. On the
other hand, genes included in cluster g_13 (annotated as myofibril) show
specific up-regulation in LAA CMs as compared to RAA in chronic
sheep. Genes in this cluster include those coding for Titin (TTN),
Myomesin (MYOM1) or Myosin heavy chain beta (MYH7). Titin is the
largest protein in humans and is essential for normal myocardial function.
GWAS studies have found loss of function variants in TTN to be statisti-
cally associated with a diagnosis of early-onset AF.27,28 MYH7 encodes
the slow molecular motor b-MyHC29 that expresses only in the atria
during cardiac development and not in the adult, but its expression is ele-
vated in atrial myocytes of patients with chronic AF as well as in the
ovine model of chronic AF.30 Thus, our analysis identifies many of the
previously reported changes in human and other animal models.
3.5 Mitochondria content increases
during AF
Our functional enrichment analysis also uncovered novel and unexpected
molecular changes associated to AF. For example, we identified a single
category enriched in the proteomic but not transcriptomic data, corre-
sponding to mitochondrial respiratory Complex I (Supplementary material
online, Figure S6E). Interestingly, these proteins showed a tendency to
increase along AF progression in LAA but not in RAA. To explore
whether the increase of mitochondrial proteins affect the organization of
the respiratory chain,31 we performed Blue-Native Gel Electrophoresis
(BNGE) of mitochondrial proteins from isolated atrial CMs.
Immunodetection of Complexes I, II, III and IV (Figure 4A and
Supplementary material online, Figure S7) showed a correct and equal dis-
tribution (Supplementary material online, Figure S7A) among well-
characterized supercomplexes as well heart-specific bands for Complex
IV32 (IVn, Figure 4A). Interestingly, we observed a new band positive for
Complex I (Ix, Figure 4A) between Complex I and Supercomplex IþIII that
increased during AF progression and would merit further characterization.
Despite the fact that BNGE showed an apparent increase of both
complexes and supercomplexes through AF progression (Figure 4A),
normalization using mitochondrial voltage-dependent anion channel,
VDAC1 (Supplementary material online, Figure S7B and C) revealed no
changes through AF progression, suggesting that their apparent increase
could be due to an increment of the total mitochondrial mass. If so, we
would expect that other proteins located in the mitochondria increase
their expression during AF progression. In fact, if we analyse proteins
that show a significant difference in the LC/MS-MS data, these are highly
represented among those that increase their expression in CMs from
LAA or RAA of chronic sheep as compared to controls (Figure 4B and
Supplementary material online, Table S3). To confirm this hypothesis, we
quantified mitochondrial DNA (mtDNA) copy number versus nuclear
DNA as standard indicator of the mitochondrial mass. The results
showed that while there is no difference in mtDNA content between
left and right, in both LAA and RAA isolated CMs from the transition
and chronic samples, mtDNA increases an average of three-fold com-
pared to controls (Figure 4C). This strongly suggests that during AF pro-
gression, the mitochondrial mass increases together with the
mitochondrial electron transport chain subunits without changing their
relative distribution.
3.6 Chromatin dysregulation in
cardiomyocytes is a hallmark of AF
An unexpected observation was the enrichment in terms related to
chromatin, that were present in four independent clusters (g_1, g_25,
g_26, and g_29; Supplementary material online, Table S3). The general
trend was for a decrease in expression in both LAA and RAA, mainly in
CMs (Supplementary material online, Figure S6F). We analysed the ex-
pression in CM RNA-seq data of 142 genes encoding chromatin related
factors.14 We identified an overall decrease in expression in transition
and chronic sheep as compared to controls (Figure 5A). Down-regulated
genes included those coding for different histone modifying enzymes
(methyl-transferases, de-methylases, acetyl-transferases), related to
both active and inactive chromatin and transcription, as well as nucleo-
some remodellers such as the NuRD complex (Figure 5A).
This observation led us to ask if there was a global dysregulation of
chromatin in CMs from sheep with induced AF. We first measured the
total amount of histones present in CMs by western blot (Figure 5B and
Supplementary material online, Figure S8A), and found that there was an
important decrease of both Histone 3 and Histone 4 in transition and
chronic individuals. Interestingly, the decrease in histones was much
more pronounced in LAA than RAA (Figure 5B).
The general decrease in chromatin remodellers together with lower
amounts of histones suggested that an overall de-compaction of chroma-
tin could be occurring in CMs during AF. Therefore, we decided to ex-
amine the expression of TEs from the sheep genome as a proxy for
































chromatin deregulation. Under normal circumstances, TEs are silenced
except in very early stages of development.33 However, it has been re-
cently proposed that TE expression can occur in some pathological
states and also during organismal ageing.34 We reanalysed our transcrip-
tomic data to assess TE expression, as this information is filtered out dur-
ing standard pre-processing of RNA-seq data. In first place, we
annotated the sheep genome’s complement of TEs (Supplementary ma-
terial online, Figure S8B), finding that the most abundant was the homo-
logue of bovine BovB long interspersed element (LINE).35 Expression of
BovB LINE was increased in CMs during progression of AF, both in tran-
sition and chronic individuals and in left and right atria (Figure 5C).
Altogether, these results suggest that progression of AF results in a
global disorganization of chromatin, with a reduction of histones and
remodelling factors, leading to a de-repression of TE expression.
3.7 Changes in the posterior left atrium
mirror those in the atrial appendage
So far, our analysis was based on tissue and cells from the atrial append-
age, but we wished to know if the molecular changes occurring in this tis-
sue were representative of those happening in other anatomical
locations of the atria. We took advantage of samples available from con-
trol and transition sheep from the PLA, which together with the pulmo-
nary veins are the prime substrate for AF initiation and maintenance.
Furthermore, we obtained six samples to analyse by RNA-seq from each
condition, allowing us to test how reproducible our transcriptomic
analysis was using small sample numbers (see above). We subsampled
our dataset taking all possible combinations from 3 to 6 samples for each
condition and carrying our differential gene expression analysis. We then
compared the degree of overlap between the sets of differentially
Figure 4 AF progression increases mitochondrial mass. (A) Immunodetection of the respiratory super-complexes after BNGE of digitonin-solubilized mi-
tochondrial proteins. Complexes and super-complexes detected are indicated. (B) Volcano plot of LAA and RAA cardiomyocyte LC/MS-MS data indicating
significantly up-regulated (orange) and down-regulated (blue) proteins that localize to mitochondria in chronic sheep as compared to controls. (C) mtDNA
copy number quantification in LAA and RAA by qPCR relative to nuclear DNA. n = 3; *P < 0.05; **P < 0.01; unpaired Student’s t-test.
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Figure 5 Cardiomyocyte chromatin is disorganized in AF. (A) Heatmap showing the expression (as z-scores) of 142 genes encoding for chromatin remod-
ellers in cardiomyocytes from LAA and RAA of control, transition, and chronic AF sheep. Three main clusters are observed (left), with cluster I showing de-
creased expression in transition and chronic conditions. This cluster includes mayor histone modifiers and nucleosome remodellers (shown on the right).
(B) Quantification of the expression of Histone 3 (left) and Histone 4 (right) during AF progression in cardiomyocytes form right and left atria, as measured
by western blot. Values were normalized to those of TNNT2 as cardiomyocyte marker. n = 3; *P-value < 0.05, Student’s unpaired t-test. (C) BovB transpos-
able element transcript abundance (counts) in the RNA-seq data from LAA and RAA cardiomyocytes during AF progression. n = 3; *P-value < 0.05, DEseq
default method.



































































































expressed genes (DEGs) for different sample numbers. We observed
that the great majority of DEGs were identified in all conditions, for both
up-regulated, down-regulated, and all DEGs (Supplementary material
online, Figure S9A). Therefore, we can safely conclude that in our analysis,
despite being small, a sample number of three as we have used for the
atrial appendage, is sufficient to draw robust statistically valid conclusions
regarding differential expression.
We first compared the changes in gene expression between control
and transition states from the PLA and the LAA. We observed a very
high correlation for all genes, both for LAA tissue and isolated CMs
(Figure 6A). Furthermore, many of the critical genes we had identified as
differentially expressed in the LAA, such as RCAN1, LGALS3, or PCP4,
were also changing in the PLA (Figure 6B and Supplementary material on-
line, Table S4). Unsupervised hierarchical clustering resulted in 12 differ-
ent clusters showing a clear difference in expression between control
and transition PLA (Figure 6C). Functional enrichment of GO terms
(Supplementary material online, Table S5) showed how terms related to
heart contraction and the CM were up-regulated in transition samples,
while those related to blood vessel development down-regulated
(Figure 6C). Furthermore, changes in expression in the PLA of genes cod-
ing for chromatin related factors (Supplementary material online, Figure
S9B) showed a very similar trend to that we had previously observed in
genes differentially expressed in the atrial appendage along disease pro-
gression (Figure 5A). Overall, this analysis shows that the molecular
changes that take place during AF progression are very similar between
different anatomical locations of the atria.
3.8 Gene expression identifies differences
in the rate of AF progression of individual
sheep
An unexpected observation from the clustering analysis was that transi-
tion samples separated into two subgroups (top burgundy and blue bars,
Figure 6C), and that a number of the clusters generated showed differences
between these subgroups (clusters 1, 7, 9, 11, and 12; boxed in Figure 6C).
This subgrouping was also evident when we analysed the expression of
chromatin factors (Supplementary material online, Figure S9B). When
searching for a possible explanation of the differences in the transition
samples, we observed that these were perfectly matched by the rate of
AF progression in these sheep. This was measured as the days taken for
an individual sheep from the start of tachypacing to a period of 7 days in
AF with no tachypacing (the criterion used to define transition samples).
Three sheep took more than 180 days, and were classified as slow pro-
gressing, while other three took less than 70 days and were considered
fast (Supplementary material online, Figure S9C and Table S1).
Those clusters showing differences in expression between slow and
fast transition sheep were not enriched for any particular GO term.
However, a careful inspection of the genes included in them
(Supplementary material online, Table S4) showed an unsuspected enrich-
ment in genes related to neural cells, such as those coding for the adhesion
molecules NCAM1 or NRCAM, the ion channel HCN2, components of
signalling pathways such as TGFB3 or CAMK2B, or members of the Slit/
Robo axon guidance signalling pathway such as SLIT1 and ROBO2
(Figure 6C). Finally, it was interesting to find that genes belonging to clus-
ter 1, that show a stronger down-regulation in fast progressing sheep
compared to controls than slow sheep, include prominent regulators of
cell proliferation such as KIT, NOTCH1, PRMT8, or PLK1 (Figure 6C). Future
studies will be required to explore if reduced proliferation of cells in the
PLA leads to a faster progression of AF to the permanent condition.
3.9 Molecular changes that occur during
disease progression are enriched for AF
risk-associated genes
GWAS have highlighted the genetic basis for a predisposition to AF, and
inform in an unbiased manner of possible molecular mechanisms under-
lying the disease.24,36,37 On the other hand, our study interrogates the
molecular changes that occur as a consequence of the disease, and pro-
vides information of the molecular mechanisms responsible for its pro-
gression. We asked to what extent did these two processes overlap, and
if genes that increase susceptibility to AF were also changing during dis-
ease progression.
To do so, we first obtained from the public NHGRI-EBI GWAS
Catalogue non-redundant lists of genes associated to electrophysiologi-
cal cardiovascular diseases (CVD), including AF, and electrophysiological
traits such as PR or QT interval, and as a control genes associated to
myocardial CVD (such as myocardial infarction or heart failure), obtain-
ing 668 and 212 genes respectively (Supplementary material online,
Table S6). We also used a third GWAS group of the non-redundant
genes listed in two recently published independent GWAS meta-
analyses which have extended previous AF associations to hundreds of
loci15,16 (240 genes, Supplementary material online, Table S6). We then
compared these different lists to the set of selected features (4409 differ-
entially expressed genes and proteins) identified in our study of the LAA
and RAA, and as a control, the set of all expressed features (11 960). We
found that genes associated to electrophysiological CVD and traits, as
well as those identified as associated to AF by meta-GWAS, are enriched
in the set of features that change during AF progression in our sheep
model, while genes associated with myocardial CVD are not (Figure 7A).
Among these are genes coding for ion channels (such as KCNJ5 or
SCN5A), developmental transcription factors (PITX2, TBX5), chromatin
regulators (such as KDM3A or MBD5), structural proteins (MYOCD,
MYOT), and cell-to-cell communication (GJA1 or IL6R) proteins
(Figure 7B). These results show that gene regulatory networks and mo-
lecular pathways that are involved in the genetic predisposition to AF
are also altered because of disease progression towards an atrial cardio-
myopathy due to external factors, including stress and inflammation.16
4. Discussion
We have taken advantage of a well-established, clinically relevant large
animal model to analyse in vivo the molecular changes that occur in the
atria during progression of AF from paroxysmal to persistent. We dem-
onstrate that the hallmarks of AF-induced atrial remodelling change only
at early transitional stages, but not at later stages of the disease, and that
the left atrium undergoes significantly more profound changes in its ex-
pression programme than the right atrium.
The temporal dynamics of the above changes in gene and protein ex-
pression corresponded closely with the electrical and structural remod-
elling we demonstrated previously in the sheep,3 and were remarkably
similar to those obtained retrospectively in patients undergoing remote
transmissions of AF frequency via implantable cardioverter-defibrillator/
cardiac resynchronization therapy with defibrillator or pacemaker devi-
ces.9 In both animal and human studies, the duration of the AF episodes
and the electrical activation frequency increased progressively during the
transition, and the rate was different for each animal or patient, reaching
a maximum at the onset of persistent AF. In addition, the activation fre-
quency did not increase after 1 year of self-sustained persistent AF in the
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Figure 6 Transcriptomic profiling of posterior left atria tissue. (A) Correlation of the logFC of expression in transition versus control of PLA tissue with
LAA tissue (upper panel) and with LAA cardiomyocytes (lower panel). Differentially expressed genes in LAA are shown in red and blue, respectively.
Pearson correlation values are indicated in the right bottom corner of each graph. (B) Volcano plot of transition vs. control for PLA tissue. Differentially
expressed genes at 5% FDR are shown in orange (up-regulated in transition compared to controls) or blue (down-regulated in transition compared to con-
trols). (C) Heatmap showing the expression (as z-scores) of the 2185 genes found differentially expressed in the PLA when comparing transition versus
control sheep (n = 6). Two main branches of the clustering segment the differentially expressed genes into down-regulated and up-regulated for this
comparison (transition–control). Various clusters suggest the existence of two different gene expression patterns, for fast and slow sheep to reach persis-
tent AF (indicated as burgundy and blue bars on top of the heatmap, respectively). Genes and GO terms related to individual clusters are indicated on
the left.
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Figure 7 Overlap of intrinsic genetic determinants and extrinsic genetic changes in AF. (A) Graph showing the percentage of differentially expressed
(pink) and all expressed (green) features (genes and proteins) in the sheep AF model that are present in the selected list of genes associated by GWAS to
electrophysiological CVD and traits, myocardial CVD, and genes associated to AF in two recent meta-analysis loci.15,16 Differences between both sets was
assessed by a hypergeometric test with Benjamini–Hochberg correction for multiple testing. ***P-value < 1e-04. (B) Representative genes included in the
overlap between differentially expressed features in the sheep AF model and AF-associated genes, coding for ion channels (left row), developmental tran-
scription factors and chromatin regulators (middle row), and other cellular components (right row). (C) Diagram depicting the progression of AF from an
early state (transition), where electrical, metabolic, and transcriptional changes take place, to a later long-standing persistent (chronic) state when structural
remodelling that leads to dilation and hypertrophy occur as a secondary effect. We also propose that chromatin remodelling is a critical factor in sustaining
the disease state.



































































































sheep or 3.4 years in patients. Moreover, at the end of the transition,
electrical remodelling in the sheep was accompanied by structural
remodelling resulting in atrial dilatation and fibrosis.3,11
Different experimental models have been used to understand the
pathophysiology of AF.5,26 But so far, large animal models8,38,39 have
proven to be the most adequate in terms of ease in pacing and similarity
to the process of progression in humans.3,8 Importantly, sheep models
have shown their utility to study molecular determinants of disease pro-
gression.10,11 We have performed transcriptomic and proteomic profil-
ing of both atrial tissue and isolated CMs from LAA and RAA of sheep
that had been in self-sustained persistent AF for a short period (7 days)
and from animals for more than a year in self-sustained persistent AF.
We have also analysed the transcriptomic changes driven by AF in the
PLA, finding them very similar to those in the LAA. By comparing these
two time points of disease progression to control animals, we were able
to explore the networks and pathways underlying AF.
The initial global analysis of the data provided an unexpected finding.
The changes in gene or protein expression during AF occurred early,
during the transition from paroxysmal to persistent, but thereafter were
unchanged for up to one year despite AF persistence. This occurs both
in whole atrial appendage tissue and isolated CMs, and for either gene or
protein expression. Furthermore, when analysing the main drivers of the
variability underlying our data, apart from the expected components re-
lated to disease progression and left/right identity, we found a third
driver that we related to a ‘transition state’. We hypothesize the transi-
tion state reflects the early changes taking place in the initial period of
AF, which in the sheep model are reflected by a rapid increase in domi-
nant frequency (Figure 7C). Together, these results suggest that the un-
derlying molecular mechanisms distinguish between paroxysmal and
persistent but not between persistent and permanent forms of AF. This
outcome makes it necessary to conduct a more detailed analysis of the
early stages of disease progression. Another interesting finding from our
global analysis is that changes in the LAA are more pronounced than in
the RAA, in line with the view that AF is a left atria disease,40 with subse-
quent changes occurring in the right atrium.
The functional annotation of the data, and the comparison of whole
tissue and CM-specific RNA-seq, allowed us to identify processes and
pathways that have been previously associated with AF. For example, fi-
brosis, inflammation and changes in ion channels have been previously
described as part of the mechanisms responsible for perpetuation of
AF,41 and contractile dysfunction in AF (referred to as atrial cardiomyop-
athy) is emerging as an important contributor to the disease.42,43 Equally,
we observed changes in genes related to calcium-handling, which have a
critical role in AF.44,45 The calcium ion-channel subunit encoding gene
CACNA1C shows reduced expression in CMs during AF progression,
which correlates well with functional studies using the same model.3,11
On the other hand, RCAN1, involved in calcineurin signalling, is one of
the most up-regulated genes in our analysis, while PCP4, which exerts an
opposite effect in this pathway,25 is strongly down-regulated. It has been
shown that rapid atrial activity results in Ca2þ loading, that in turn trig-
gers the Ca2þ-dependent calmodulin–calcineurin–NFAT pathway to
cause the down-regulation of ICaL and action potential duration reduc-
tion in the atrial cardiomyocytes.46 RCAN1 has also been implicated in
TRPC1/C4 channel-mediated activation of the calcineurin-NFAT path-
way,47 and identified as top hub gene in human AF samples.48 We also
observed an increase in mitochondrial mass in our model that coincides
with the observation of higher protein levels of respiratory complexes in
patients with persistent AF.49,50
Our analysis has revealed changes to chromatin as a major conse-
quence of AF in the sheep. Global down-regulation of chromatin factors,
together with a drop in core histone levels and an increase in the expres-
sion of TEs, suggestive of chromatin decompaction, all occur during AF
progression. Several of these epigenomic-related changes have been as-
sociated with the decline that occurs during ageing.51 Reduction of histo-
nes can lead to loss of heterochromatin with derepression of TEs, which
would normally be silenced.52 Hypomethylation of DNA also accompa-
nies chromatin decompaction and has been observed in other CVD such
as atherosclerosis,53,54 and overall epigenomic changes have been argued
to be a cause for the progression of common human diseases.55,56 It is in-
teresting that the analysis of subcellular structures in a goat model of AF
revealed dispersed heterochromatin in the nucleus of AF CMs, compared
to clustered aggregates found in CMs from sinus rhythm animals, as one
of the earliest changes.38 Therefore, our results suggests that a general
decrease in nuclear organization is a hallmark of AF, and could be ex-
plored as an early marker of the disease in humans.57 Furthermore, chro-
matin remodelling would lead to altered epigenomic states that reinforce
the disease-related gene expression programme (Figure 7C).
When analysing the transcriptomic data from the PLA, we were able
to find differences in gene expression that correlate with sheep atria that
transition to persistent AF at different rates. Interestingly, among these
we identified many genes related to neural cells, which together with
other observations on the role of the neural system in AF,58,59 suggests a
neural input on how quickly AF progresses. We also observed that fast
progressing sheep had lower expression of proliferation-related genes.
These observations open up novel avenues that could help to identify
and treat those patients that will progress more rapidly to permanent,
and therefore more adverse, forms of AF.
There is substantial evidence in the literature indicating that AF is heri-
table. Classical genetics have documented several chromosomal loci and
genetic mutations in myocardial sodium, potassium, and potassium-
adenosine triphosphate channels.60,61 In our study, a number of those
genes (such as NPPA, MYL4, PRKAG2, LMNA, SCN5A, and KCNH2) are dif-
ferentially expressed in the sheep atria during AF progression in our
study. In fact, the increase in AF frequency during the progression to per-
sistent AF is a reflection of electrical remodelling in the form of action
potential duration abbreviation brought about by differential changes to
ion channels, such as decreases in sodium and L-type calcium currents or
increase in inward rectifier potassium current.3 On the other hand,
more than 100 new genetic loci have been associated to an increased
risk of AF by GWAS, pointing to yet unexplored mechanisms underlying
the disease.62 The analysis of the variants underlying these associations
will reveal how they underpin specific atrial substrates or conditions that
can modify molecular functions leading to progression of AF.63 This
source of variation might help explain the large variability in the rate of
AF remodelling and progression that has been observed in animals and
in patients. Nevertheless, research efforts taking together personal ge-
netic profiles, clinical risk factors and monitoring of AF progression64
along with atrial cell remodelling63 should help to better understand risk
and progression of AF. It may also help to predict the rate of AF progres-
sion and the time to completion of atrial electrical remodelling, thus im-
proving stratification and the personalized care of AF patients.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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Seppälä I, Malik R, Horimoto ARVR, Perez M, Sinisalo J, Aeschbacher S, Thériault S,
Yao J, Radmanesh F, Weiss S, Teumer A, Choi SH, Weng L-C, Clauss S, Deo R,
Rader DJ, Shah SH, Sun A, Hopewell JC, Debette S, Chauhan G, Yang Q, Worrall
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Translational perspective
We have generated a detailed molecular map of atrial fibrillation (AF) progression in a clinically relevant large-animal model. Such data would be
very difficult if not impossible to obtain from patients. Our results provide a framework for a comprehensive molecular analysis of the disease, point-
ing to novel avenues of research towards identifying early events that can lead to therapeutically targets to prevent AF-induced atrial remodelling.
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